Seeing Is Believing
Eiger Biopharmaceuticals's activity chart (see below) currently has 23 price targets and 18 ratings on display.
Analysts average stock forecasts to be materialized ratio is 38.1% with an average time for these price targets to be met of 427.21 days.
Most recent stock forecast was given by from CITI on 29-Aug-2023.
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Buy Since 26-Jun-2019
$26
3 years 12 days ago
(29-Aug-2023)
1/3 (33.33%)
$-224.2 (-89.61%)
694
Buy
$3
$0.95 (46.34%)
$3
3 years 2 months 10 days ago
(30-Jun-2023)
2/2 (100%)
$2.3 (328.57%)
294
Buy Since 09-May-2018
$150
$147.95 (7217.07%)
3 years 2 months 11 days ago
(30-Jun-2023)
0/3 (0%)
$128.88 (610.23%)
Buy Since 19-Dec-2018
$44
4 years 3 days ago
(07-Sep-2022)
2/2 (100%)
$-118 (-72.84%)
1215
Buy Since 16-May-2018
$29
$26.95 (1314.63%)
$690
4 years 5 months 24 days ago
(17-Mar-2022)
1/3 (33.33%)
$-210.4 (-87.89%)
370
What is EIGR (Eiger Biopharmaceuticals) average time for price targets to be met?
Which analyst most recently updated their price target on EIGR (Eiger Biopharmaceuticals)?
Which analyst has the most public recommendations on EIGR (Eiger Biopharmaceuticals)?
Which analyst is the currently most bullish on EIGR (Eiger Biopharmaceuticals)?
Which analyst is the currently most reserved on EIGR (Eiger Biopharmaceuticals)?